NBI-74330

Alias: NBI74330; NBI 74330; NBI-74330.

Cat No.:V5173 Purity: ≥98%

COA Product Data Instructions for use SDS

NBI-74330 (NBI74330) is a novel, potent and selective antagonist for CXCR3 (CXC chemokine receptor 3) with potential anticancer, immunomodulatory and antiinflammatory activities.

NBI-74330 Chemical Structure CAS No.: 855527-92-3
Product category: CXCR

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Other Forms of NBI-74330:

rac-NBI-74330

Official Supplier of:

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Biological Data

Product Description

NBI-74330 (NBI74330) is a novel, potent and selective antagonist for CXCR3 (CXC chemokine receptor 3) with potential anticancer, immunomodulatory and antiinflammatory activities. It shows strong inhibition of (125I)CXCL10 and (125I)CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively, and inhibits CXCR3 with IC50 values ranging from 7 to 18 nM. In mice lacking the LDL receptor, NBI-74330 reduces the development of atherosclerotic plaque. Glioma growth is stimulated by the chemokine receptor CXCR3. Since CXCR3 antagonism directly inhibits gliomas, treating human GBM may benefit from targeting this receptor as a therapeutic target.

Biological Activity I Assay Protocols (From Reference)

Targets

[¹²⁵I]CXCL10-CXCR3 ( Ki = 1.5 nM ); [¹²⁵I]CXCL11-CXCR3 ( Ki = 3.2 nM )

ln Vitro

NBI74330 (also known as NBI 74330; NBI-74330) exhibits a strong suppression of [¹²⁵I]CXCL11-specific binding to membranes derived from CXCR3-expressing transfected CHO cells (CXCR3-CHO) at a Ki=3.6 nM. Compared to CXCL9 (Ki=45.2 nM) and CXCL10 (Ki=12.5 nM), NBI-74330 is 12- and 3.5-fold more potent, respectively, at inhibiting [¹²⁵I]CXCL11 binding to CXCR3-CHO cell membranes. NBI-74330 inhibits calcium mobilization in response to CXCL11 and CXCL10 with an IC50 value of 7 nM for both ligands used at their EC80 concentrations (1 nM for CXCL11 and 30 nM for CXCL10). Specifically, CXCR3-mediated calcium mobilization is inhibited by NBI-74330. Additionally, NBI-74330 inhibits [³⁵S]GTPγS binding in the membranes of cells that naturally express CXCR3 (H9 cells; IC50 value: 5.5 nM) in a dose-dependent manner. BI-74330 inhibits CXCL11-induced chemotaxis in these cells with an IC50 of 3.9 nM[1]. NBI-74330 (30-300 nm, 1-10 μM) causes parallel, concentration-dependent rightward shifts in the CXCL11 E/[A] curve, but the maximal response of the E/[A] curve is unaffected[2].

ln Vivo

NBI74330 (NBI 74330; NBI-74330) (100 mg/kg) causes the production of an N-oxide metabolite that is also a CXCR3 antagonist, in mice[2]. The serum concentrations of mice treated with 100 mg/kg NBI-74330 (in 1% Na Doc in 0.5% 400Cp Methylcellulose) are about 1 μM. To fully block the CXCR3 receptor in vivo, this concentration is adequate[3].

Enzyme Assay

In order to use cell membrane fractions in competitive radioligand binding reactions, they are resuspended in 50 mM HEPES, 10 mM MgCl₂, 100 mM NaCl, and 1 mM CaCl₂ at pH 7.2. The assay buffer (50 mM HEPES, 10 mM MgCl₂, 100 mM NaCl, 1 mM CaCl₂, 0.1% BSA, pH 7.2) is gradually added to low-binding 96-well plates containing 5-μL membrane protein (5 μg). The reactions are carried out in duplicate and comprise 25 μL unlabeled chemokine at indicated concentrations and 25 μL radiolabeled chemokine ligand (approx 70 nM; [¹²⁵I]CXCL11 and [¹²⁵I]CXCL10 with specific activities of 1500 and 2200 Ci/mmol, respectively). The reaction is shaken and incubated for 45 minutes at room temperature in order to reach equilibrium. The extraction of membranes through filtration through a UniFilter GF/C filter plate using a UniFilter-96 vacuum manifold (pretreated filters with 1% polyethylenimine) yields the amount of bound radioligand. The membranes are then washed twice with 400-μL wash buffer (10 mM HEPES, 5 mM MgCl₂, 1 mM CaCl₂, and 500 mM NaCl, pH 7.3), and radioactivity is measured using liquid scintillation with a TopCount NXT. The measurement of the dissociation half-life of [¹²⁵I]CXCL11 is conducted using CXCR3-CHO membranes, which are first allowed to equilibrate with radiolabel (approximately 70 nM) for 30 minutes. After that, excess cold CXCL11 (31 nM final) is added, either in the presence or absence of varying concentrations of NBI-74330. Membrane-bound [¹²⁵I]CXCL11 is measured in duplicate on the same plate at each time point, along with total binding ([¹²⁵I]CXCL11 without inhibitors) and nonspecific binding ([¹²⁵I]CXCL11 plus excess cold CXCL11 added at the same time).

Animal Protocol

Two weeks prior to collar insertion, female LDLr^−/− mice, aged 10 weeks (n=8–12 per group), are given a Western-xstyle diet containing 15% cocoa butter and 0.25% cholesterol. For the duration of the experiment, 20 mice receive daily subcutaneous injections of 100 mg/kg NBI-74330. The mice are put to sleep after eight weeks of being fed a diet typical of the West and having their organs removed for histology, fluorescence-activated cell sorter (FACS) analysis, and RNA isolation. Blood is drawn from nonfasted animals by tail bleeding, and enzymatic colorimetric techniques are used to measure the levels of serum cholesterol and triglycerides.

References

[1]. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71.

[2]. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol. 2007 Dec;152(8):1260-71.

[3]. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):251-7.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula	C32H27F4N5O3
Molecular Weight	605.5821
Exact Mass	605.21
Elemental Analysis	C, 63.47; H, 4.49; F, 12.55; N, 11.56; O, 7.93
CAS #	855527-92-3
Related CAS #	473722-68-8 (racemate);855527-92-3 (R-isomer)
Appearance	Solid powder
SMILES	CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
InChi Key	XMRGQUDUVGRCBS-UHFFFAOYSA-N
InChi Code	InChI=1S/C32H27F4N5O3/c1-3-44-24-11-9-23(10-12-24)41-30(39-29-25(31(41)43)7-5-15-38-29)20(2)40(19-22-6-4-14-37-18-22)28(42)17-21-8-13-27(33)26(16-21)32(34,35)36/h4-16,18,20H,3,17,19H2,1-2H3
Chemical Name	N-[1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide
Synonyms	NBI74330; NBI 74330; NBI-74330.
HS Tariff Code	2934.99.9001
Storage	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)	DMSO: ~100 mg/mL (~165.1 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 2.5 mg/mL (4.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More Solubility in Formulation 3: ≥ 2.5 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.)

Solubility (In Vitro)

DMSO: ~100 mg/mL (~165.1 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.5 mg/mL (4.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 2.5 mg/mL (4.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6513 mL	8.2565 mL	16.5131 mL
	5 mM	0.3303 mL	1.6513 mL	3.3026 mL
	10 mM	0.1651 mL	0.8257 mL	1.6513 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Biological Data

The selectivity and specificity of a murine CXCR3 internalization assay.Br J Pharmacol. 2007 Dec; 152(8): 1260–1271.

PK/PD parameters of NBI-74330 (100 mg kg−1) following oral administration to mice.

An external file that holds a picture, illustration, etc.
Object name is 0707519f5.jpg

PK/PD parameters of NBI-74330 (100 mg kg−1) following subcutaneous administration to mice.Br J Pharmacol. 2007 Dec; 152(8): 1260–1271.

Murine CXCR3 receptor classification using receptor internalization and GTPγS assays.
Tolerance of the murine CXCR3 internalization assay to plasma.Br J Pharmacol. 2007 Dec; 152(8): 1260–1271.